| 000 | 01330 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250515235319.0 | ||
| 264 | 0 | _c20101203 | |
| 008 | 201012s 0 0 eng d | ||
| 022 | _a1178-2048 | ||
| 024 | 7 |
_a10.2147/vhrm.s10952 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFoley, James E | |
| 245 | 0 | 0 |
_aWeight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. _h[electronic resource] |
| 260 |
_bVascular health and risk management _cAug 2010 |
||
| 300 |
_a541-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAdamantane _xanalogs & derivatives |
| 650 | 0 | 4 |
_aBlood Glucose _xanalysis |
| 650 | 0 | 4 |
_aBody Weight _xdrug effects |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 |
_aDipeptidyl-Peptidase IV Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aGlucose _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadverse effects |
| 650 | 0 | 4 | _aInsulin Resistance |
| 650 | 0 | 4 |
_aNitriles _xpharmacology |
| 650 | 0 | 4 |
_aPyrrolidines _xpharmacology |
| 650 | 0 | 4 | _aVildagliptin |
| 650 | 0 | 4 |
_aWeight Gain _xdrug effects |
| 700 | 1 | _aJordan, Jens | |
| 773 | 0 |
_tVascular health and risk management _gvol. 6 _gp. 541-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2147/vhrm.s10952 _zAvailable from publisher's website |
| 999 |
_c20065511 _d20065511 |
||